These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Update on HER-kinase-directed therapy in prostate cancer. Gross ME; Jo S; Agus DB Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160 [TBL] [Abstract][Full Text] [Related]
5. Trastuzumab--mechanism of action and use. Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG N Engl J Med; 2007 Oct; 357(16):1664; author reply 1665-6. PubMed ID: 17942884 [No Abstract] [Full Text] [Related]
6. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors]. Nielsen DL; Andersson M Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954 [TBL] [Abstract][Full Text] [Related]
7. [Breast cancer and Her-2]. Hatake K Nihon Rinsho; 2007 Jun; 65 Suppl 6():87-94. PubMed ID: 17682144 [No Abstract] [Full Text] [Related]
8. [Epidermal growth factor receptor family and targeted anticancer therapy]. Liu TH Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):577-9. PubMed ID: 17134561 [No Abstract] [Full Text] [Related]
9. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]. Dalmases A; Rojo F; Rovira A; Albanell J Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407 [No Abstract] [Full Text] [Related]
10. [Targeted therapies: last focus on EGF receptor inhibitors in breast cancer]. Magné N; Milano G Bull Cancer; 2004 Dec; 91 Suppl 4():S257-60. PubMed ID: 15899618 [TBL] [Abstract][Full Text] [Related]
11. Targeting the epidermal growth factor receptor in colorectal carcinoma. Kurtin SE Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985 [TBL] [Abstract][Full Text] [Related]
12. Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer. Krawczyk P; Chocholska S; Milanowski J Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):113-7. PubMed ID: 15314969 [TBL] [Abstract][Full Text] [Related]
13. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials. Tuma RS J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725 [No Abstract] [Full Text] [Related]
14. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Meric-Bernstam F; Hung MC Clin Cancer Res; 2006 Nov; 12(21):6326-30. PubMed ID: 17085641 [TBL] [Abstract][Full Text] [Related]
15. Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice. Morse L ONS News; 2006; 21(8 Suppl):59-60. PubMed ID: 16925155 [No Abstract] [Full Text] [Related]
16. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Nahta R; O'Regan RM Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425 [TBL] [Abstract][Full Text] [Related]